Aegros

As a Biotech, our value is not in physical assets but in the intangible assets we generate through our R&D. As intangible assets traditionally sit off-balance sheet, existing financial reports do not provide investors with the tools to evaluate/compare our business with alternative Biotech investments. Working with EverEdge has helped us to identify and value our intangible assets, which in turn has enabled us to articulate the true value of our Company more effectively to our existing and potential investors.